secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000950170-23-005084
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Biosciences Q4 net loss $67M; ARC-7 domvanalimab combo doubles PFS to 12 months
--------------------------------------------------------------------------------

- Q4 2022 net loss $67M vs net income $280M in Q4 2021; full-year net loss $267M vs net income $53M.
- Revenue $34M in Q4 2022, down from $355M in Q4 2021; cash $1.1B, sufficient into 2026.
- ARC-7 interim data: domvanalimab+zimberelimab mPFS 12.0 months vs 5.4 months for zimberelimab alone.
- Four ongoing registrational Phase 3 studies for domvanalimab; updated ARC-7 data expected at ASCO June 2023.
- AB521 (HIF-2a inhibitor) Phase 1/1b enrolling 50mg cohort; initial data expected late 2023 or early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000095017023005084/0000950170-23-005084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000095017023005084/rcus-20230228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer